Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Depreciation & Amortization (CF) (2023 - 2025)

Immunocore Holdings' Depreciation & Amortization (CF) history spans 3 years, with the latest figure at $834000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 28.47% year-over-year to $834000.0; the TTM value through Dec 2025 reached $3.3 million, down 22.31%, while the annual FY2025 figure was $3.3 million, 22.31% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $834000.0 at Immunocore Holdings, up from $798000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.2 million in Q4 2024 and bottomed at $780000.0 in Q2 2025.
  • The 3-year median for Depreciation & Amortization (CF) is $1.0 million (2024), against an average of $963333.3.
  • The largest annual shift saw Depreciation & Amortization (CF) grew 12.98% in 2024 before it dropped 28.47% in 2025.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $1.0 million in 2023, then increased by 12.98% to $1.2 million in 2024, then dropped by 28.47% to $834000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Depreciation & Amortization (CF) are $834000.0 (Q4 2025), $798000.0 (Q3 2025), and $780000.0 (Q2 2025).